Skip to main content
. 2023 Feb 16;14:1092401. doi: 10.3389/fimmu.2023.1092401

Figure 1.

Figure 1

The balance between cancer immunology and transplant tolerance. Through the activation of effector T cells, the ICIs can not only reduce tumor burden but also increase the risk of graft rejection. IL-2, interleukin-2; IFN-γ, interferon-γ; TNF-α, tumor necrosis factor-α.